First Time Loading...
C

Clarus Therapeutics Holdings Inc
NASDAQ:CRXT

Watchlist Manager
Clarus Therapeutics Holdings Inc
NASDAQ:CRXT
Watchlist
Price: 0.021 USD -19.54% Market Closed
Updated: Jun 11, 2024

Clarus Therapeutics Holdings Inc
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Clarus Therapeutics Holdings Inc
Total Liabilities & Equity Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Total Liabilities & Equity Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
C
Clarus Therapeutics Holdings Inc
NASDAQ:CRXT
Total Liabilities & Equity
$51.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Total Liabilities & Equity
$172B
CAGR 3-Years
0%
CAGR 5-Years
3%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Total Liabilities & Equity
$99B
CAGR 3-Years
-4%
CAGR 5-Years
23%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Total Liabilities & Equity
$221.1B
CAGR 3-Years
12%
CAGR 5-Years
7%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
Total Liabilities & Equity
$105.8B
CAGR 3-Years
5%
CAGR 5-Years
5%
CAGR 10-Years
0%
Eli Lilly and Co
NYSE:LLY
Total Liabilities & Equity
$63.9B
CAGR 3-Years
11%
CAGR 5-Years
11%
CAGR 10-Years
6%

See Also

What is Clarus Therapeutics Holdings Inc's Total Liabilities & Equity?
Total Liabilities & Equity
51.7m USD

Based on the financial report for Dec 31, 2021, Clarus Therapeutics Holdings Inc's Total Liabilities & Equity amounts to 51.7m USD.

What is Clarus Therapeutics Holdings Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 1Y
167%

Over the last year, the Total Liabilities & Equity growth was 167%.